307. Canavan disease Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 6 / Drugs : 11 - (DrugBank : 5) / Drug target genes : 2 - Drug target pathways : 2
Drugs and their primary sponsors and trial info
AAV9 BBP-812
Aspa Therapeutics
2021 Phase 1/Phase 2 NCT04998396 United States;
GTA (Glyceryl triacetate)
Shaare Zedek Medical Center
2008 - NCT00724802 Israel;
GTA glyceryl triacetate
Shaare Zedek Medical Center
2008 - NCT00724802 Israel;
GTA: Glyceryltriacetate
Sheba Medical Center
2006 Phase 1 NCT00278707 Israel;
Levetiracetam
Myrtelle Inc.
2021 Phase 1/Phase 2 NCT04833907 United States;
Lithium Gluconate (drug) Glyceryl Triacetate GTA (drug)
Assistance Publique - Hôpitaux de Paris
2009 Phase 2 NCT00657748 France;
Prednisolone
Myrtelle Inc.
2021 Phase 1/Phase 2 NCT04833907 United States;
RAAV-Olig001-ASPA
Myrtelle Inc.
2021 Phase 1/Phase 2 NCT04833907 United States;
Aspa Therapeutics
2021 Phase 1/Phase 2 NCT04998396 United States;
GTA (Glyceryl triacetate)
Shaare Zedek Medical Center
2008 - NCT00724802 Israel;
GTA glyceryl triacetate
Shaare Zedek Medical Center
2008 - NCT00724802 Israel;
GTA: Glyceryltriacetate
Sheba Medical Center
2006 Phase 1 NCT00278707 Israel;
Levetiracetam
Myrtelle Inc.
2021 Phase 1/Phase 2 NCT04833907 United States;
Lithium Gluconate (drug) Glyceryl Triacetate GTA (drug)
Assistance Publique - Hôpitaux de Paris
2009 Phase 2 NCT00657748 France;
Prednisolone
Myrtelle Inc.
2021 Phase 1/Phase 2 NCT04833907 United States;
RAAV-Olig001-ASPA
Myrtelle Inc.
2021 Phase 1/Phase 2 NCT04833907 United States;